CAP-100

• Description :

  CAP-100 is a monoclonal antibody that targets CCR7. CAP-100 neutralizes the ligand-binding site and signaling of CCR7. CAP-100 strongly inhibits CCR7-induced migration, extravasation, homing, and survival in chronic lymphocytic leukemia (CLL) samples. CAP-100 triggers potent tumor cell killing, mediated by host immune mechanism. CAP-100 shows a favorable toxicity profile on relevant hematopoietic subsets. CAP-100 is involved in research on anti-tumor and disease such as CLL[1].

• UNSPSC :

  12352203

• Target :

  CCR

• Related Pathways :

  GPCR/G Protein; Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cancer; Inflammation/Immunology

• Purity :

  99.84

• Smiles :

  [CAP-100]

• Molecular Weight :

  (146.48 kDa)

• References & Citations :

  [1]Cuesta-Mateos C, et al., Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL. MAbs. 2021 Jan-Dec;13 (1) :1917484.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  -80°C

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 1